Click on the resources tab to view the ePoster and Sci-Talk.
Vaccine with a novel broad-spectrum immunologic adjuvant to combat COVID-19
Vaccine with a novel broad-spectrum immunologic adjuvant which can trigger a wide spectrum of immune cells can be used to provide protection against COVID-19. One of the main challenge for COVID-19 vaccine development is lack approved adjuvants which can induce the required responses. In an attempt to solve this problem, I designed a novel broad-spectrum immunologic vaccine adjuvant which can exhibit immunomodulatory effects on a wide spectrum of immune cells. A novel broad-spectrum immunologic vaccine adjuvant can enhance immune responses by producing more antibodies, improving the function of the phagocytic cells which destroy viruses and modulating neutrophile and monocytes (macrophages) activity. I have given the name ‘Covid Bullet’ for this broad-spectrum immunologic vaccine adjuvant which have antigen pockets on its surface. Covid-bullet (novel broad-spectrum immunologic vaccine adjuvant) with SARS CoV2 spike protein on its surface can be used as oral vaccine to provide protection against Covid-19 which is the current global problem.
Mulugeta Feyisa, D.V.M.
Ethiopian Agricultural Transformation Agency